Evidence map›Paper›PMID 11487512›Full record

ArticleBritish journal of pharmacology2001

The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs.

D J Williamson, R G Hill, S L Shepheard, R J Hargreaves

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Review
  3. Intra-arterial lidocaine administration of lidocaine in middle meningeal artery for short-term treatment of subarachnoid hemorrhage-related headaches.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2025
    Article
  4. Review
  5. The 5-HTNature reviews. Neurology · 2023
    Review
  6. Article
  7. Article
  8. Targeting the central projection of the dural trigeminovascular system for migraine prophylaxis.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019
    Article
  9. CGRP in Animal Models of Migraine.Handbook of experimental pharmacology · 2019
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Pharmacology.Handbook of clinical neurology · 2010
    Article
  15. Article
  16. Article
  17. Rizatriptan in the treatment of migraine.Neuropsychiatric disease and treatment · 2006
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

D J WilliamsonDepartment of Pharmacology, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, UK. david_williamson@merck.com
R G Hill
S L Shepheard
R J Hargreaves
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

These studies investigated the pharmacology of neurogenic dural vasodilation in anaesthetized guinea-pigs. Following introduction of a closed cranial window the meningeal (dural) blood vessels were visualized using intravital microscopy and the diameter constantly measured using a video dimension analyser. Dural blood vessels were constricted with endothelin-1 (3 microg kg(-1), i.v.) prior to dilation of the dural blood vessels with calcitonin gene-related peptide (CGRP; 1 microg kg(-1), i.v.) or local electrical stimulation (up to 300 microA) of the dura mater. In guinea-pigs pre-treated with the CGRP receptor antagonist CGRP((8-37)) (0.3 mg kg(-1), i.v.) the dilator response to electrical stimulation was inhibited by 85% indicating an important role of CGRP in neurogenic dural vasodilation in this species. Neurogenic dural vasodilation was also blocked by the 5-HT(1B/1D) agonist rizatriptan (100 microg kg(-1)) with estimated plasma levels commensurate with concentrations required for anti-migraine efficacy in patients. Rizatriptan did not reverse the dural dilation evoked by CGRP indicating an action on presynaptic receptors located on trigeminal sensory fibres innervating dural blood vessels. In addition, neurogenic dural vasodilation was also blocked by the selective 5-HT(1D) agonist PNU-142633 (100 microg kg(-1)) but not by the 5-HT(1F) agonist LY334370 (3 mg kg(-1)) suggesting that rizatriptan blocks neurogenic vasodilation via an action on 5-HT(1D) receptors located on perivascular trigeminal nerves to inhibit CGRP release. This mechanism may underlie one of the anti-migraine actions of the triptan class exemplified by rizatriptan and suggests that the guinea-pig is an appropriate species in which to investigate the pharmacology of neurogenic dural vasodilation.

Indexed as

AnesthesiaAnimalsBenzamidesCalcitonin Gene-Related PeptideChromansDose-Response Relationship, DrugDura MaterGuinea PigsHumansIndolesMaleMeningeal ArteriesMigraine DisordersPeptide FragmentsReceptor, Serotonin, 5-HT1BReceptor, Serotonin, 5-HT1D4-fluoro-N-(3-(1-methyl-4-piperidinyl)-1H-indol-5-yl)benzamideBenzamidesCalcitonin Gene-Related Peptidecalcitonin gene-related peptide (8-37)ChromansHTR1B protein, humanIndolesPeptide FragmentsPNU 142633FReceptor, Serotonin, 5-HT1BReceptor, Serotonin, 5-HT1DReceptors, SerotoninrizatriptanSerotonin Receptor AgonistsTriazolesTryptamines

Identifiers

PMID11487512
PMCPMC1572868
OpenAlexW2025257256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.